Cerus Corporation CERS
1.95 USD -0.12 (-5.80%)
At closeNov 10, 2026, 4:41 PM EST
1.95 0.00 0.00%
After hours · Nov 10, 4:41 PM ET
1.92 Day range 2.08
1.47 52-week range 3.47
- YTD
- -5.34%
- 1 year
- +21.87%
News
benzinga.com Adeia Posts Downbeat Q3 Earnings, Joins Bioventus, Apple And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. futures mixed as Adeia plunges 23% after missing Q3 estimates and cutting FY26 guidance; Bioventus, Emergent and others also fall premarket.
fool.com Cerus: 3 Key Takeaways for Long-Term Investors A shift to higher-margin kit distribution and a successful red blood cell trial position Cerus for path to GAAP profitability.
benzinga.com Why Aehr Test Systems Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket Aehr surged 15% after strong Q1 results and raised FY27 guidance; Mercer, HUB Cyber and Parabolic led gainers, while VCIG and Jaguar fell.
seekingalpha.com Cerus Corporation (CERS) Q3 2026 Earnings Call Transcript Cerus Corporation ( CERS ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Timothy Lee - Head of Investor Relation Vivek Jayaraman - CEO, President & Director Kevin Green - VP…
marketbeat.com Cerus Q3 Earnings Call Highlights Cerus NASDAQ: CERS reported third-quarter product revenue growth of 10% year over year and reaffirmed its 2026 revenue outlook, while also announcing positive top-line results from its Phase III…
benzinga.com Cerus Q3 2026 Earnings Call Transcript Cerus (NASDAQ:CERS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
reuters.com Cerus' blood-safety system meets main goal in late-stage trial Cerus' blood-safety system meets main goal in late-stage trial
benzinga.com Cerus Affirms FY2026 Sales Guidance of $229.000M-$231.000M vs $248.850M Est Cerus (NASDAQ:CERS) affirms FY2026 sales outlook from $229.000 million-$231.000 million to $229.000 million-$231.000 million vs $248.850 million estimate.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 16.2% to $4.67 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Cerus…
businesswire.com Cerus Corporation Announces Third Quarter 2026 Financial Results CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2026, and provided a business update. "Our solid…
businesswire.com Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results from the Phase 3 RedeS (NCT03037164) trial. “Over the past decade, pathogen reduction…
businesswire.com Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026 CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2026 financial results will be released on Monday, November 2, 2026, after the close of the…
businesswire.com Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the implementation and real-world experience with INTERCEPT Platelets and…
defenseworld.net RxSight (NASDAQ:RXST) & Cerus (NASDAQ:CERS) Critical Analysis Cerus (NASDAQ: CERS - Get Free Report) and RxSight (NASDAQ: RXST - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based…
seekingalpha.com Cerus: This Blood-Safety Underdog Should Be Earning More Respect Cerus (CERS) is pivoting toward higher-value therapeutic products while reducing its research cost burden, aided by substantial government funding. Q2 2026 results signal an inflection point: product…
defenseworld.net Assenagon Asset Management S.A. Has $920,000 Stock Holdings in Cerus Corporation $CERS Assenagon Asset Management S.A. lessened its holdings in Cerus Corporation (NASDAQ: CERS) by 74.8% during the second quarter, according to the company in its most recent Form 13F filing with the…
benzinga.com Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analyst estimates for Q3. Other stocks also dip in pre-market.
seekingalpha.com Cerus Corporation (CERS) Q2 2026 Earnings Call Transcript Cerus Corporation (CERS) Q2 2026 Earnings Call Transcript
marketbeat.com Cerus Q2 Earnings Call Highlights Cerus NASDAQ: CERS reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure…
benzinga.com Cerus Q2 EPS $(0.01), Inline, Sales $57.441M Miss $60.933M Estimate Cerus (NASDAQ:CERS) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 66.67 percent increase over losses of $(0.03) per share from the same period…
benzinga.com Cerus Raises FY2026 Sales Guidance from $227.000M-$231.000M to $229.000M-$231.000M vs $245.200M Est Cerus (NASDAQ:CERS) raises FY2026 sales outlook from $227.000 million-$231.000 million to $229.000 million-$231.000 million vs $245.200 million estimate.
businesswire.com Cerus Corporation Announces Second Quarter 2026 Financial Results CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the second quarter ended June 30, 2026, and provided a business update. “This quarter we made…
defenseworld.net Amova Asset Management Americas Inc. Sells 193,353 Shares of Cerus Corporation $CERS Amova Asset Management Americas Inc. reduced its stake in shares of Cerus Corporation (NASDAQ: CERS) by 4.1% during the first quarter, according to the company in its most recent 13F filing with the…
businesswire.com Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026 CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2026 financial results will be released on Thursday, July 30, 2026, after the close of the…
benzinga.com Cerus Announces William Greenman Ceases As President And CEO, Becomes Executive Chairman Effective July 1, 2026 https://www.sec.gov/ix?doc=/Archives/edgar/data/0001020214/000102021426000015/cers-20260706.htm
businesswire.com Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion…
benzinga.com Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,502 shares of Kodiak AI
businesswire.com Cerus Corporation Closes New Debt Facility of Up to $110 Million CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the closing of a new debt facility with MidCap Financial (MidCap), providing up to $110 million. The facility…
businesswire.com Bradley L. Radoff Announces Intent to Withhold Votes from Chair and CEO William Greenman and Director Ann Lucena HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, a significant shareholder of Cerus Corporation (NASDAQ: CERS) (“Cerus” or the “Company”), today announced his intention to withhold support for the…
benzinga.com Top 2 Health Care Stocks That May Plunge This Month Health care stocks flashing warning for momentum investors. RSI measures stock strength, overbought when above 70. AVNS +127% past 6 months, AGL +212% past month.
seekingalpha.com Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis Cerus' Q1 2026 product revenues grew another 24% YoY. This was mainly thanks to strong platelet demand and rapid IFC adoption. Management raised its 2026 product revenue guidance to $227-$231…
benzinga.com Top 3 Health Care Stocks That May Collapse This Month Stocks AVNS, APLS, and CERS in healthcare sector flashing warning to momentum-sensitive investors. High RSI values & price action indicate overbought conditions. AVNS at 90. APLS at 86. CERS at 86.…
benzinga.com This Caterpillar Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday Top analysts upgraded APD, CAT, CERS, PPC, and HSY stocks with increased price targets. Check out analysts' views on these stocks before buying.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Cerus Q1 2026 Earnings Call Transcript
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Cerus Raises FY2026 Sales Guidance from $224.000M-$228.000M to $227.000M-$231.000M vs $242.400M Est Cerus (NASDAQ:CERS) raises FY2026 sales outlook from $224.000 million-$228.000 million to $227.000 million-$231.000 million vs $242.400 million estimate.
- benzinga.com Cerus Q1 EPS $(0.01) Beats $(0.04) Estimate, Sales $53.661M Beat $53.167M Estimate Cerus (NASDAQ:CERS) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.04) by 75 percent. This is a 75 percent increase over losses of $(0.04) per share…
benzinga.com Earnings Scheduled For April 30, 2026 - benzinga.com Cerus Signs Four-Year Supply Agreement With Établissement Français Du Sang For INTERCEPT Blood And Platelet Pathogen Inactivation System The EFS distributes approximately 330,000 units of platelets annually across 13 regional centers in continental France and overseas territories. The INTERCEPT Blood System for platelets has been used…
benzinga.com MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session MDB stock fell 27.2% in pre-market trading after reporting Q4 earnings of $1.65 per share, revenue of $695.07M, and Q1 guidance below estimates.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com Cerus Q4 Earnings Assessment - benzinga.com Cerus Affirms FY2026 Sales Guidance of $224.000M-$228.000M Cerus (NASDAQ:CERS) affirms FY2026 sales outlook from $224.000 million-$228.000 million to $224.000 million-$228.000 million.
- benzinga.com Cerus Q4 EPS $(0.01), Inline, Sales $57.751M Miss $58.075M Estimate Cerus (NASDAQ:CERS) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of…
- benzinga.com Earnings Scheduled For March 2, 2026
benzinga.com Earnings Preview For Cerus 
benzinga.com TG Therapeutics, Clover Health Investments, Nutrien And Other Big Stocks Moving Higher On Wednesday - benzinga.com Reported Earlier, Cerus Reports Preliminary 2025 Product Revenue Of $206.1M, Up 14% YoY; Guides 2026 Product Revenue Of $224M–$228M On 9%–11% Growth And IFC Revenue Of $20M–$22M Preliminary Full-Year 2025 Product Revenue of $206.1 MillionFull-Year 2026 Product Revenue Expected to be $224 Million to $228 Million, Reflecting 9%-11% Growth, Year-Over-Year